Investment Thesis
Arcutis is fundamentally unprofitable with -10.7% net margin and minimal revenue growth of just 1.1% YoY, making it a high-risk biotech despite positive cash generation. The company carries $109.4M in debt with -1.2x interest coverage, creating financial stress that threatens sustainability if profitability does not materialize soon. While positive operating cash flow and solid liquidity ratios ($34.8M cash, 2.68x current ratio) provide near-term runway, the company must demonstrate significant revenue acceleration or profitability improvement to justify its current capital structure.
Strengths
- Positive operating cash flow of $2.2M despite operating losses, suggesting underlying business viability
- Strong liquidity position with current ratio of 2.68x and quick ratio of 2.46x
- Moderate leverage at 0.58x debt-to-equity with $189.6M stockholders' equity providing financial cushion
Risks
- Unprofitable operations with -8.6% operating margin and -10.7% net margin; operating losses of $9.1M
- Severely anemic revenue growth of only 1.1% YoY in highly competitive pharmaceutical sector; unsustainable at current burn rate
- Negative interest coverage of -1.2x indicates operating income cannot service $109.4M debt load; refinancing risk
- Thin free cash flow margin of 2.1% is unsustainable if operations deteriorate; only $34.8M cash available
- Zero capital expenditures is unusual for pharma; may indicate stalled pipeline development or outsourcing problems
Key Metrics to Watch
- Revenue growth trajectory and pipeline progress (must accelerate significantly from 1.1%)
- Path to operating profitability and operating margin improvement
- Free cash flow sustainability and cash burn rate relative to $34.8M cash reserves
- Debt refinancing needs and ability to service interest obligations from operations
Financial Metrics
Revenue
105.4M
Net Income
-11.3M
EPS (Diluted)
$-0.09
Free Cash Flow
2.2M
Total Assets
460.0M
Cash
34.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-8.6%
Net Margin
-10.7%
ROE
-6.0%
ROA
-2.5%
FCF Margin
2.1%
Balance Sheet & Liquidity
Current Ratio
2.68x
Quick Ratio
2.46x
Debt/Equity
0.58x
Debt/Assets
58.8%
Interest Coverage
-1.22x
Long-term Debt
109.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T09:09:50.857901 |
Data as of: 2026-03-31 |
Powered by Claude AI